Trevi Therapeutics, Inc. · NASDAQ:TRVI
The Vanguard Group reported a 5.01% stake in Trevi Therapeutics, Inc. (Schedule 13G)
Event Dec 31, 2025 · Filed Jan 30, 2026
The Vanguard Group reported a 5.01% stake in Trevi Therapeutics, Inc., 6,434,655 shares, as a passive investor on Dec 31, 2025. Filed Jan 30, 2026 (Schedule 13G).
- Stake
- 5.01%
- Shares
- 6,434,655
- Intent
- Passive
- What changed
- Crossed above 5%
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| The Vanguard Group | 5.01% | 6,434,655 |
Source
Related
- Trevi Therapeutics, Inc.
- The Vanguard Group
- Trevi Therapeutics, Inc. shareholders
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026
- Form 4 · Heffernan Michael Thomas · Sep 17, 2026
- Schedule 13G/A · FMR LLC · Aug 6, 2026
- Schedule 13D/A · New Enterprise Associates 16, L.P. · May 7, 2026
- Schedule 13G/A · FMR LLC · May 6, 2026
- Schedule 13D/A · New Enterprise Associates 16, L.P. · Feb 13, 2026